Akt1-IN-8
Akt1-IN-8 (Compound JL18) is a potent and oral bioavailable (41%) inhibitor of AKT1 kinase, with an IC50 of 8.8 nM. Akt1-IN-8 exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 can reduce phosphorylated GSK3β levels[1].
Product Specifications
CAS Number
2247688-87-3
UNSPSC
12352005
Target
Akt
Related Pathways
PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
O=C(C(CNC(C)C)C1=CC=C(C=C1)Br)N2CCN(CC2)C3=C4C(Br)=NNC4=NC=N3
Molecular Formula
C21H25Br2N7O
Molecular Weight
551.28
References & Citations
[1]Sun J, et, al. The discovery of novel N-heterocyclic-based AKT inhibitors with potential efficacy against prostate cancer. Eur J Med Chem. 2025 May 5:289:117435.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-C246000-50MG 50 mg
6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-γ-Cyclodextrin
Sign In for Pricing
View Details 
ICH1056-25mg 25 mg
Anti-Mouse CD32/CD16 (2.4G2) In Vivo Antibody - Low Endotoxin
Sign In for Pricing
View Details 
